Key result
Maintaining physiological calcium prevents artifactual increases in diabetic platelet TxB2 production seen with citrated plasma.
Why the study?
Platelets of diabetic patients show increased thromboxane B2 production in vitro under low ionized calcium conditions, contrasting with normal in vivo production, suggesting a need to clarify the effect of physiological ionized calcium on thromboxane B2 production.
Does maintaining physiological ionized calcium concentrations in vitro normalize thromboxane B2 production by platelets from diabetic patients compared to controls?
Case-Control (n=77)
Does maintaining physiological ionized calcium concentrations in vitro normalize thromboxane B2 production by platelets from diabetic patients compared to controls?
The apparent in vitro hyperreactivity and increased thromboxane B2 production of diabetic platelets is an artifact caused by low ionized calcium in citrated plasma, and normalizes at physiological calcium concentrations.
Answers are grounded in this paper and cite their sources.
Cautions against citrated plasma assays for diabetic platelet studies; challenges prior hyperreactivity reports and leaves open physiological calcium effects on clinical risk.
Platelets of patients with diabetes and no evidence of macroangiopathy produce normal amounts of thromboxane (Tx) B2 in vivo, whereas they usually show increased production in vitro. Since in vitro studies have been usually performed in citrated PRP, we tested the hypothesis that the discrepancy between in vivo and in vitro studies is due to the low concentration of plasma ionized calcium ([Ca2+]o) that is present in citrated PRP. In fact, low [Ca2+]o artifactually potentiates the platelet TxB2 production in vitro. Forty patients with diabetes mellitus and 37 matched controls were studied. Blood was anticoagulated with citrate, the thrombin inhibitor D-phenylalanyl-l-prolyl-l-chloromethylketone (PPACK) or both anticoagulants. Platelet aggregation, release of 14C-serotonin and TxB2 production were induced in platelet rich plasma (PRP) by several agonists. The following results were obtained: i) Citrated PRP: Arachidonic acid induced aggregation (p < 0.01) and TxB2 production (p < 0.02) were significantly greater in patients than in controls. No statistically significant differences were found with other agonists. ii) PPACK PRP: No statistically significant difference was found between diabetic platelets and controls. iii) PPACK plus citrate PRP: The results were not different from those obtained with citrate alone. Therefore, our results show that diabetic platelets produce normal amounts of TxB2 in vitro when the [Ca2+]o is physiological.
No takes yet. Share an insight, caveat, or question.
Falcón et al. (1993) conducted a case-control in Diabetes mellitus (n=77). Diabetes mellitus vs. Matched controls was evaluated on Arachidonic acid induced aggregation and TxB2 production (p=<0.01). Platelets from diabetic patients produced normal amounts of thromboxane B2 in vitro when physiological ionized calcium concentrations were maintained, unlike the artifactual increases seen in citrated plasma.
Synapse has enriched 10 related papers. Consider them for comparative context: